Akanda

AKAN
1.0803.57% ( -0.040 )
Closed: Oct 20, 16:00:00 (EDT)

Current ValuationThe current P/E ratio is -0.01, above the reasonable range, cheaper than 0% of the time in the past 1 years, and the industry ranks 64/256, the industry Median -1.20.

-0.0114xP/E
Stock price$1.08Earnings per share$-94.36

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-60.73x154.63%$63.44B
BAYZFUSBayer Aktiengesellschaft
-24.08x--$48.51B
BAYRYUSBayer
-23.82x--$47.98B
VTRSUSViatris
-52.16x107.68%$21.42B
ELANUSElanco Animal Health
-56.99x129.36%$11.34B
VREOFUSVIREO GROWTH INC
-126.24x--$8.47B
AXSMUSAxsome Therap
-43.62x21.51%$8.36B
BLTEUSBelite Bio
-60.76x29.87%$6.22B
CURLFUSCuraleaf Holdings, Inc.
-115.64x--$6.02B
MANEUSVeraDermics
-50.92x97.44%$5.31B
RGCUSRegencell Bioscience
-442.47x--$5.18B
DFTXUSDefinium Therapeutics
-13.33x54.55%$4.71B
EWTXUSEdgewise Therapeutics
-21.89x207.38%$4.32B
AMLXUSAmylyx Pharmaceuticals
-23.74x1.76%$3.61B
TARSUSTarsus Pharmaceuticals
-67.07x201.10%$3.12B
ELVNUSEnliven Therapeutics
-28.53x5.59%$3.02B
MBXUSMBX Biosciences
-24.71x31.12%$2.58B
BHCUSBausch Health
-2.19x569.84%$2.40B
SUPNUSSupernus Pharma
-21.81x66.18%$2.40B
PRGOUSPerrigo
-1.29x100.10%$2.24B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.